SOLICITATION NOTICE
B -- Testing Services
- Notice Date
- 7/29/2010
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-HG-2010-262-RSF
- Archive Date
- 8/19/2010
- Point of Contact
- Rashida S. Ferebee, Phone: 3014352605
- E-Mail Address
-
ferebeers@nhlbi.nih.gov
(ferebeers@nhlbi.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSALS. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. It is the intent of the National Heart, Lung, and Blood Institute (NHLBI) for the National Human Genome Research Institute (NHGRI), to negotiate/award a purchase order to Albert Einstein College of Medicine located at 1410 Pelham Parkway South, Bronx, NY, 10461 for the testing of the efficacy of tocopherol isomers in NPC1-null mice. This is a contract between NIH Therapeutics for Rare and Neglected Diseases laboratories (TRND) and Albert Einstein College of Medicine, Dr. Steven Walkley Laboratory (Walkley Laboratory) in the Department of Neuroscience, Albert Einstein College of Medicine for the testing service of the effect of two tocopherol isomers (delta- and alpha- tocopherols) from TRND on the NPC1-null mouse model. Services outlined in this proposal include the treatment of the mice with 2-3 doses of alpha- and delta-tocopherols and collecting of the data to weekly including weights, functional observation battery (SHIRPA), evaluation and periodic videotaping for open field analysis, related behavioral assessments, and finally, survival data. At the end of experiments, the tissues will be processed for routine histology, and for in depth CNS analysis for cholesterol/ganglioside storage. Blood and tissue samples will also be collected and frozen for biomarker assessment;also for ganglioside analyses and related assessments in collaboration with others. The Walkley laboratory is chosen as the sole source based upon their previous experience studying NPC1 mouse model in several compounds including cyclodextrin. Their previous experience provides a unique understanding of therapeutic effect of cyclodextrin on the reduction of cholesterol accumulation in NPC cells and neurological symptoms of the NPC mice. Additionally, the Walkley lab is well recognized as the world leader in studying the NPC mouse models. Dr. Walkley combines skills in neuropathology and cellular neuroscience in order to address key issues in the study of pathogenic cascades involving the brain affected by lysosomal diseases. In addition to the cell biology and pathogenesis of storage disorders, his laboratory is also focused on studies examining potential treatment strategies for these diseases, including cell-mediated approaches as well as substrate reduction therapy. He serves on the scientific advisory boards of three lysosomal disease groups - the National Niemann-Pick Disease Foundation (for which he is chair of the SAB), The National MPS Society, and the International Society for Mannosidosis and Related Disorders. TRND has previously worked with the Walkley lab in last two year as part of collaborative research consortium for therapeutics development for NPC though SORA (a patient-scientist NPC group). Their previous knowledge of the drug development for NPC adds to the sole source justification for awarding this contract to the Walkley laboratory. The Walkley lab’s ability to perform lipid analysis on the tissue samples from the mouse model is a unique capability for the NPC drug test. Lastly, the Walkley laboratory has advised the TRND group in term of drug discovery for NPC project. These experiences are invaluable and further the sole source justification. Mandatory Certification: Animal Welfare Assurance Certificate on file with the “Office for Protection from Research Risks” at the National Institutes of Health. Period of performance: August 15, 2010-December 14, 2010 This acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, and is exempt from the requirements of FAR Part 6, Competition Requirements. The North American Industry Classification (NAICS) Code is 611310 and the Size Standard is $7.0 Million. This notice of intent is not a request for competitive proposals. The determination by the Government not to compete the proposed purchase order based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing synopsis number NHLBI-PB-HG-2010-262-RSF may be submitted by mail to the National Heart, Lung and Blood Institute, Office of Acquisitions, Procurement Branch, 6701 Rockledge Drive, Suite 6151, Bethesda, MD 20892-7902, Attention: Rashida Ferebee, by fax transmission to (301) 480-3345 or by email to ferebeers@nhlbi.nih.gov This action is under the authority of 41.U.S.C.253(c)(1), as set forth in FAR 13.106(b)(2), and HHSAR 306-302-1. Interested parties responding to this announcement need to do so by 9:00am Eastern Standard Time on August 5, 2010.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-HG-2010-262-RSF /listing.html)
- Place of Performance
- Address: Albert Einstein College of Medicine, 1410 Pelham Parkway South, Bronx, New York, 10461, United States
- Zip Code: 10461
- Zip Code: 10461
- Record
- SN02223002-W 20100731/100730000237-1b5be870755852126fb6e2a67b2efece (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |